The biochemical basis of inherited metabolic disorders and their clinical implications
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Inherited metabolic disorders remain among the most diagnostically challenging conditions in pediatric and adult medicine, with over 1,500 recognized entities affecting virtually every biochemical pathway in human cells. This research analyzed the diagnostic performance of five screening methodologies and the treatment response profiles of six therapeutic approaches across eight inherited metabolic disorders, drawing on both prospective clinical data from Italian patients and comprehensive biochemical profiling from laboratory analyses conducted between September 2018 and March 2020. We enrolled 168 patients with confirmed or suspected metabolic disorders at two academic centers in Italy, collecting plasma, urine, and dried blood spot specimens for parallel analysis using tandem mass spectrometry, enzyme activity assays, molecular genetic testing, urine metabolite quantification, and dried blood spot screening protocols. Diagnostic sensitivity varied markedly across methods: genetic testing achieved the highest overall sensitivity at 97.9-99.7% depending on disorder type, while tandem mass spectrometry performed best for amino acid disorders with 96.7-98.3% sensitivity but dropped to 58.9% for mucopolysaccharidoses. Enzyme assays showed the opposite pattern, reaching 95.8% sensitivity for Gaucher disease but falling below 80% for amino acid metabolism defects. Biomarker heatmap analysis revealed that each disorder produced a characteristic biochemical fingerprint with one or two markedly elevated analytes against a background of mildly disturbed markers. Treatment response analysis demonstrated that no single therapeutic strategy was universally effective across disorder categories. Dietary restriction achieved a 91% response index for phenylketonuria but fell below 20% for lysosomal storage diseases. Enzyme replacement therapy showed the reverse pattern, with response indices of 71-87% for lysosomal disorders but negligible benefit for amino acidopathies. Combination approaches pairing enzyme replacement with substrate reduction therapy produced the strongest outcomes for Gaucher disease, where individual response indices of 87% and 79% yielded a combined improvement exceeding either modality alone. Emerging therapies including pharmacological chaperones and gene therapy showed promising early response profiles, particularly for Fabry disease (67% chaperone response) and Pompe disease (62% gene therapy response). These findings reinforce the principle that effective management of inherited metabolic disorders requires precise biochemical diagnosis followed by disorder-specific, often multimodal therapeutic strategies tailored to the individual patient's enzymatic deficiency and clinical presentation.
Fields of Study & Subjects
Metabolism and Genetic Disorders
Lysosomal Storage Disorders Research
Glycogen Storage Diseases and Myoclonus
Publication details
- Journal / source
- International Journal of Clinical Biology and Biochemistry
- Volume
- 8
- Issue
- 3
- Pages
- 07–13
- Publication date
- 1 February 2026
- Language
- EN